Tengion Inc. organ regeneration technology the Tengion Neo-Bladder, is expected to be featured on the CBS Evening exploring the current landscape and future potential of regenerative medicine.
Tengion Inc., a clinical stage regenerative medicine company focused on the development of neo-organs and neo-vessels, announced today that Steven Nichtberger, M.D., President and Chief Executive Officer, will be presenting at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on Tuesday, February 5, 2008 at 9:20 a.m. EST. The conference will be held at the Grand Hyatt Hotel in New York City.
Tengion's Autologous Organ Regeneration Platform, with a focus on the development of the company's first investigational product, the Tengion Neo-Bladder™, was expected to be featured on the CBS Evening News on Wednesday, February 6th at 6:30 PM Eastern Time (please check your local listings for your CBS affiliate's schedule.) Tengion's President and CEO, Dr. Steven Nichtberger was interviewed for the story on Tengion. This news coverage will be part of a two-night series reported by CBS News National Correspondent Wyatt Andrews that explores the current landscape and future potential of regenerative medicine.
Tengion, a clinical stage biotechnology company, has pioneered the Autologous Organ Regeneration Platform(TM) that catalyzes the body's innate ability to regenerate. Tengion's neo-organs and neo-tissues in development, such as bladders and vessels, combine biocompatible materials and a patient's own (autologous) cells to regenerate diseased and failing organs and tissues. Tengion's product candidates have the potential to cure -- rather than treat -- organ and tissue failure, enabling people to lead healthier lives without donor transplants or the side effects of related therapies. For more information on the company and current clinical trials, visit Tengion online at: www.tengion.com
CBS to air segment on Tengion Neo-Bladder product
Tengion Launches Third Phase 2 Clinical Trial Of Regenerated Human ...
tengion
Tengion Launches Third Phase 2 Clinical Trial of Regenerated Human …
Subscribe to:
Post Comments (Atom)
0 comments
Post a Comment